NEUROCRINE BIOSCIENCES INC (NBIX)
US64125C1099 - Common Stock
Overall NBIX gets a fundamental rating of 8 out of 10. We evaluated NBIX against 565 industry peers in the Biotechnology industry. NBIX gets an excellent profitability rating and is at the same time showing great financial health properties. NBIX is growing strongly while it also seems undervalued. This is an interesting combination This makes NBIX very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year NBIX was profitable.
In the past year NBIX had a positive cash flow from operations.
NBIX had positive earnings in each of the past 5 years.
In the past 5 years NBIX always reported a positive cash flow from operatings.
1.2 Ratios
NBIX has a better Return On Assets (10.92%) than 96.44% of its industry peers.
NBIX's Return On Equity of 14.19% is amongst the best of the industry. NBIX outperforms 96.44% of its industry peers.
Looking at the Return On Invested Capital, with a value of 13.96%, NBIX belongs to the top of the industry, outperforming 97.15% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for NBIX is below the industry average of 13.59%.
The last Return On Invested Capital (13.96%) for NBIX is above the 3 year average (9.89%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.92% | ||
| ROE | 14.19% | ||
| ROIC | 13.96% |
ROA(3y)6.18%
ROA(5y)8.97%
ROE(3y)8.92%
ROE(5y)13.75%
ROIC(3y)9.89%
ROIC(5y)11.96%
1.3 Margins
NBIX's Profit Margin of 17.21% is amongst the best of the industry. NBIX outperforms 96.62% of its industry peers.
NBIX's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 26.23%, NBIX belongs to the top of the industry, outperforming 97.33% of the companies in the same industry.
NBIX's Operating Margin has improved in the last couple of years.
NBIX has a Gross Margin of 98.52%. This is amongst the best in the industry. NBIX outperforms 97.69% of its industry peers.
NBIX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.23% | ||
| PM (TTM) | 17.21% | ||
| GM | 98.52% |
OM growth 3Y-12.58%
OM growth 5Y20.67%
PM growth 3Y-30.22%
PM growth 5Y23.12%
GM growth 3Y-0.38%
GM growth 5Y-0.21%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), NBIX is creating some value.
Compared to 1 year ago, NBIX has more shares outstanding
The number of shares outstanding for NBIX has been increased compared to 5 years ago.
NBIX has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 11.87 indicates that NBIX is not in any danger for bankruptcy at the moment.
NBIX has a better Altman-Z score (11.87) than 87.90% of its industry peers.
NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 11.87 |
ROIC/WACC1.28
WACC10.87%
2.3 Liquidity
NBIX has a Current Ratio of 4.37. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
NBIX has a Current ratio of 4.37. This is comparable to the rest of the industry: NBIX outperforms 49.82% of its industry peers.
A Quick Ratio of 4.26 indicates that NBIX has no problem at all paying its short term obligations.
NBIX has a Quick ratio of 4.26. This is comparable to the rest of the industry: NBIX outperforms 50.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.37 | ||
| Quick Ratio | 4.26 |
3. Growth
3.1 Past
NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 100.54%, which is quite impressive.
Measured over the past years, NBIX shows a very strong growth in Earnings Per Share. The EPS has been growing by 70.09% on average per year.
NBIX shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.72%.
NBIX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.13% yearly.
EPS 1Y (TTM)100.54%
EPS 3Y23.01%
EPS 5Y70.09%
EPS Q2Q%51.22%
Revenue 1Y (TTM)25.72%
Revenue growth 3Y21.74%
Revenue growth 5Y33.13%
Sales Q2Q%24.72%
3.2 Future
NBIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.96% yearly.
The Revenue is expected to grow by 16.53% on average over the next years. This is quite good.
EPS Next Y73.49%
EPS Next 2Y60.22%
EPS Next 3Y53.84%
EPS Next 5Y44.96%
Revenue Next Year24.44%
Revenue Next 2Y20.46%
Revenue Next 3Y19.24%
Revenue Next 5Y16.53%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 36.60, NBIX can be considered very expensive at the moment.
Based on the Price/Earnings ratio, NBIX is valued cheaper than 94.48% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.54. NBIX is valued slightly more expensive when compared to this.
With a Price/Forward Earnings ratio of 21.98, NBIX is valued on the expensive side.
NBIX's Price/Forward Earnings ratio is rather cheap when compared to the industry. NBIX is cheaper than 94.31% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.99, NBIX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.6 | ||
| Fwd PE | 21.98 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 95.55% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, NBIX is valued cheaper than 95.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.41 | ||
| EV/EBITDA | 19.08 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NBIX has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as NBIX's earnings are expected to grow with 53.84% in the coming years.
PEG (NY)0.5
PEG (5Y)0.52
EPS Next 2Y60.22%
EPS Next 3Y53.84%
5. Dividend
5.1 Amount
NBIX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEUROCRINE BIOSCIENCES INC
NASDAQ:NBIX (12/24/2024, 7:27:35 PM)
After market: 137.24 +0.71 (+0.52%)136.53
-0.46 (-0.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.13%
Inst Owner Change-0.9%
Ins Owners0.98%
Ins Owner Change-1.14%
Market Cap13.82B
Analysts83.53
Price Target166.35 (21.84%)
Short Float %3.92%
Short Ratio4.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.39%
Min EPS beat(2)-41.42%
Max EPS beat(2)-17.35%
EPS beat(4)1
Avg EPS beat(4)-23.67%
Min EPS beat(4)-59.17%
Max EPS beat(4)23.28%
EPS beat(8)2
Avg EPS beat(8)-101.77%
EPS beat(12)2
Avg EPS beat(12)-94.57%
EPS beat(16)4
Avg EPS beat(16)-71.78%
Revenue beat(2)2
Avg Revenue beat(2)3.77%
Min Revenue beat(2)1.54%
Max Revenue beat(2)5.99%
Revenue beat(4)2
Avg Revenue beat(4)0.91%
Min Revenue beat(4)-2.58%
Max Revenue beat(4)5.99%
Revenue beat(8)4
Avg Revenue beat(8)0.79%
Revenue beat(12)7
Avg Revenue beat(12)1.02%
Revenue beat(16)8
Avg Revenue beat(16)-0.07%
PT rev (1m)0.36%
PT rev (3m)-5.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26.77%
EPS NY rev (1m)2.47%
EPS NY rev (3m)-10.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.71%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)0.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.6 | ||
| Fwd PE | 21.98 | ||
| P/S | 6.16 | ||
| P/FCF | 31.41 | ||
| P/OCF | 29.02 | ||
| P/B | 5.08 | ||
| P/tB | 5.15 | ||
| EV/EBITDA | 19.08 |
EPS(TTM)3.73
EY2.73%
EPS(NY)6.21
Fwd EY4.55%
FCF(TTM)4.35
FCFY3.18%
OCF(TTM)4.71
OCFY3.45%
SpS22.15
BVpS26.85
TBVpS26.51
PEG (NY)0.5
PEG (5Y)0.52
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.92% | ||
| ROE | 14.19% | ||
| ROCE | 18.95% | ||
| ROIC | 13.96% | ||
| ROICexc | 23.1% | ||
| ROICexgc | 23.53% | ||
| OM | 26.23% | ||
| PM (TTM) | 17.21% | ||
| GM | 98.52% | ||
| FCFM | 19.62% |
ROA(3y)6.18%
ROA(5y)8.97%
ROE(3y)8.92%
ROE(5y)13.75%
ROIC(3y)9.89%
ROIC(5y)11.96%
ROICexc(3y)24.26%
ROICexc(5y)27.99%
ROICexgc(3y)25.18%
ROICexgc(5y)28.55%
ROCE(3y)13.42%
ROCE(5y)18.4%
ROICexcg growth 3Y6.34%
ROICexcg growth 5Y29.41%
ROICexc growth 3Y4.71%
ROICexc growth 5Y28.22%
OM growth 3Y-12.58%
OM growth 5Y20.67%
PM growth 3Y-30.22%
PM growth 5Y23.12%
GM growth 3Y-0.38%
GM growth 5Y-0.21%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 141.25% | ||
| Cap/Sales | 1.62% | ||
| Interest Coverage | 168.09 | ||
| Cash Conversion | 77.59% | ||
| Profit Quality | 114.05% | ||
| Current Ratio | 4.37 | ||
| Quick Ratio | 4.26 | ||
| Altman-Z | 11.87 |
F-Score8
WACC10.87%
ROIC/WACC1.28
Cap/Depr(3y)151.1%
Cap/Depr(5y)155.21%
Cap/Sales(3y)1.56%
Cap/Sales(5y)1.52%
Profit Quality(3y)204.66%
Profit Quality(5y)207.75%
High Growth Momentum
Growth
EPS 1Y (TTM)100.54%
EPS 3Y23.01%
EPS 5Y70.09%
EPS Q2Q%51.22%
EPS Next Y73.49%
EPS Next 2Y60.22%
EPS Next 3Y53.84%
EPS Next 5Y44.96%
Revenue 1Y (TTM)25.72%
Revenue growth 3Y21.74%
Revenue growth 5Y33.13%
Sales Q2Q%24.72%
Revenue Next Year24.44%
Revenue Next 2Y20.46%
Revenue Next 3Y19.24%
Revenue Next 5Y16.53%
EBIT growth 1Y69.1%
EBIT growth 3Y6.43%
EBIT growth 5Y60.65%
EBIT Next Year150.11%
EBIT Next 3Y59.71%
EBIT Next 5Y44.31%
FCF growth 1Y148.64%
FCF growth 3Y18.45%
FCF growth 5Y36.4%
OCF growth 1Y137.49%
OCF growth 3Y19.5%
OCF growth 5Y30.91%